weekly_roundup

BioTechSign Daily Catalyst Roundup - November 21, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 21, 2026

Daily Biotech Catalyst Digest: November 21, 2026

EYPT leads the current BioTechSign screen at 83.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.83.5Aclinical activity 100%, short interest 50%, dilution risk 47%
MLTXMoonLake Immunotherapeutics80.5Aclinical activity 100%, short interest 50%, publication signal 35%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%
BBIOBridgeBio Pharma73.2BPDUFA timing 100%, publication signal 100%, clinical activity 100%

Recent Grade-Change Queue

  • SMMT (Summit Therapeutics Inc.) currently grades F with a 19.6/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 25%.
  • INSM (Insmed Incorporated) currently grades D with a 38.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 58%, dilution risk 50%.
  • TENX (Tenax Therapeutics, Inc.) currently grades B with a 70.8/100 catalyst score. Main inputs: short interest 90%, clinical activity 75%, dilution risk 53%.
  • SLS (SELLAS Life Sciences Group, Inc.) currently grades F with a 28.0/100 catalyst score. Main inputs: short interest 90%, clinical activity 42%, publication signal 20%.
  • ORIC (Oric Pharmaceuticals, Inc.) currently grades D with a 46.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 50%, short interest 50%.
  • FDMT (4D Molecular Therapeutics, Inc.) currently grades C with a 52.4/100 catalyst score. Main inputs: publication signal 90%, short interest 70%, clinical activity 54%.
  • NKTR (Nektar Therapeutics) currently grades C with a 52.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 75%.
  • MLYS (Mineralys Therapeutics, Inc.) currently grades C with a 53.6/100 catalyst score. Main inputs: PDUFA timing 75%, dilution risk 51%, short interest 50%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.